Special Issue

Novel Compounds in the Treatment of the CNS Disorders, 2nd Edition

Message from the Guest Editors

Central nervous system (CNS) disorders are a broad group of neurological conditions affecting the functioning of the brain or spinal cord, and in consequence, deteriorating the quality of life of a given patient. Amongst them, bipolar disorder, depression, epilepsy/seizures, migraine, Parkinson's disease, Alzheimer's disease, Huntington's disease, attention deficit/hyperactivity disorder, and multiple sclerosis are most frequently diagnosed. These neurological conditions can be caused by several different factors, such as stroke, trauma, infections, autoimmune disorders, tumors, brain or spinal cord degeneration, structural defects, or genetic determinants. Research and medical teams focus on diverse treatment options: innovative compounds, combinations of well-known substances, as well as surgical and neurorehabilitation procedures. In our Special Issue on Novel Compounds in the Treatment of the CNS Disorders, we aim to bring together experts working in the field of neurological conditions and invite them to present their recent results from both pre-clinical and clinical studies related to the pharmacotherapy of CNS disorders.

Guest Editors

Prof. Dr. Ewa Poleszak

Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland

Prof. Dr. Anna Serefko

Department of Clinical Pharmacy and Pharmaceutical Care, Medical University of Lublin, Chodźki 1, 20-093 Lublin, Poland

Deadline for manuscript submissions

closed (30 June 2025)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/192241

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

